Literature DB >> 25957459

Novel culture medium for the axenic growth of Balamuthia mandrillaris.

Luis Fernando Lares-Jiménez1, Ricardo Alfredo Gámez-Gutiérrez2, Fernando Lares-Villa3.   

Abstract

Until now, for axenic cultivation of Balamuthia mandrillaris, the BM-3 culture medium and the Modified Chang's special medium have been the only ones recommended, but they have some disadvantages, as both require many components and their preparations are laborious. Therefore, we developed a novel culture medium for B. mandrillaris axenic cultivation. Each one of the 11 components of BM-3 was combined with Cerva's medium as basal culture medium. Ten strains of B. mandrillaris including the reference strain CDC:V039 and 9 environmental isolates were used during trials. After testing all combinations, the basal medium complemented with 10× Hank's balanced salt solution was the only one that supported confluent growth of B. mandrillaris. Cell shape and motility of trophozoites were normal. This developed medium is as useful as BM-3 for axenization. The development of a cheaper and easy-to-prepare medium for B. mandrillaris opens the possibility of increasing its study.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Axenization; Culture media; Free living amoebae; Granulomatous amoebic encephalitis

Mesh:

Substances:

Year:  2015        PMID: 25957459     DOI: 10.1016/j.diagmicrobio.2015.04.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  In Vitro Screening of the Open-Source Medicines for Malaria Venture Malaria and Pathogen Boxes To Discover Novel Compounds with Activity against Balamuthia mandrillaris.

Authors:  Christopher A Rice; Luis Fernando Lares-Jiménez; Fernando Lares-Villa; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

2.  Presence of Balamuthia mandrillaris in hot springs from Mazandaran province, northern Iran.

Authors:  A R Latifi; M Niyyati; J Lorenzo-Morales; A Haghighi; S J Seyyed Tabaei; Z Lasjerdi
Journal:  Epidemiol Infect       Date:  2016-04-18       Impact factor: 4.434

3.  Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing.

Authors:  Alexander L Greninger; Kevin Messacar; Thelma Dunnebacke; Samia N Naccache; Scot Federman; Jerome Bouquet; David Mirsky; Yosuke Nomura; Shigeo Yagi; Carol Glaser; Michael Vollmer; Craig A Press; Bette K Kleinschmidt-DeMasters; Bette K Klenschmidt-DeMasters; Samuel R Dominguez; Charles Y Chiu
Journal:  Genome Med       Date:  2015-12-01       Impact factor: 11.117

4.  Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.

Authors:  Monica M Kangussu-Marcolino; Gretchen M Ehrenkaufer; Emily Chen; Anjan Debnath; Upinder Singh
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-10-22       Impact factor: 4.284

5.  Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris.

Authors:  Matthew T Laurie; Corin V White; Hanna Retallack; Wesley Wu; Matthew S Moser; Judy A Sakanari; Kenny Ang; Christopher Wilson; Michelle R Arkin; Joseph L DeRisi
Journal:  mBio       Date:  2018-10-30       Impact factor: 7.867

6.  Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity.

Authors:  Gretchen Ehrenkaufer; Pengyang Li; Erin E Stebbins; Monica M Kangussu-Marcolino; Anjan Debnath; Corin V White; Matthew S Moser; Joseph DeRisi; Jolyn Gisselberg; Ellen Yeh; Steven C Wang; Ana Hervella Company; Ludovica Monti; Conor R Caffrey; Christopher D Huston; Bo Wang; Upinder Singh
Journal:  PLoS Negl Trop Dis       Date:  2020-03-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.